论文部分内容阅读
目的分析甲状腺组织多药耐药基因产物P-糖蛋白（P－gp）的表达状况，探讨甲状腺癌组织P－gp表达与病情发展及预后相关因素的关系。方法采用免疫组化sp法，检测P－gp表达水平。结果检测37例甲状腺癌组织；15例癌旁正常组织及17例甲状腺腺瘤组织。P-gp阳性表达率分别是45.9％（17／37）；20％（3／15）及23.5％（4／17），经统计学处理，甲状腺癌与甲状腺良性组织P－gp表达有显著性差异（P＜0．05），但良性组织之间无差异性（P＞0.05）。甲状腺癌组织P－gp表达水平与病情发展及预后相关因素（年龄、原发肿瘤、转移淋巴结、病理分类）之间，除与病理分化程度有显著性差异外（P<0．05），其余各项与P－gp表达无显著性差异（P＞0．05）。结论甲状腺癌MDR与P－gp过度表达有关，并且有其内在的本质特征，不受化疗药物诱导，不受疾病发展的影响。甲状腺癌P－gp的表达有其特殊性。
Objective To analyze the expression of P-glycoprotein (P-gp) in the thyroid tissue and to explore the relationship between the expression of P-gp in thyroid cancer tissue and the related factors of the disease progression and prognosis. Methods Immunohistochemical sp method was used to detect the expression of P-gp. Results Thirty-seven cases of thyroid cancer tissues, 15 normal tissues adjacent to cancer, and 17 cases of thyroid adenoma tissues were detected. The positive expression rate of P-gp was 45.9% (17/37); 20% (3/15) and 23.5% (4/17) respectively. After statistical analysis, the expression of P-gp in thyroid carcinoma and thyroid benign tissue was significant. Difference (P<0.05), but no difference between benign tissues (P>0.05). The level of P-gp expression in thyroid cancer tissues was related to the progression of the disease and related factors (age, primary tumors, metastatic lymph nodes, and pathological classification), except for significant difference from pathological differentiation (P<0.05). There was no significant difference in P-gp expression (P>0.05). Conclusion The thyroid cancer MDR is related to the overexpression of P-gp, and has its intrinsic essential characteristics. It is not induced by chemotherapeutic drugs and is not affected by the development of the disease. The expression of P-gp in thyroid carcinoma has its particularity.